Welcome to our dedicated page for Aligos Therapeutics news (Ticker: ALGS), a resource for investors and traders seeking the latest updates and insights on Aligos Therapeutics stock.
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company focused on therapies for liver and viral diseases, and its news flow reflects progress across this pipeline. Company announcements frequently highlight developments in chronic hepatitis B virus (HBV) programs, obesity and metabolic dysfunction-associated steatohepatitis (MASH) research, and broader corporate activities.
News items include updates on pevifoscorvir sodium, an oral capsid assembly modulator (CAM-E) under investigation for chronic HBV infection. Aligos issues press releases on clinical trial milestones, such as the initiation and enrollment of the Phase 2 B-SUPREME study, as well as data presentations at major scientific meetings. These communications describe antiviral activity, biomarker changes, and study designs that are central to understanding the company’s HBV strategy.
Investors and observers can also find coverage of ALG-055009, a THR-β agonist being studied for obesity and MASH. News from Aligos has detailed nonclinical in vivo results in diet-induced obese mouse models, showing synergistic body weight and fat mass loss when ALG-055009 is combined with incretin receptor agonists such as semaglutide or tirzepatide. Such updates provide insight into how the company positions this candidate within emerging combination approaches in cardiometabolic disease.
Beyond pipeline data, the ALGS news stream includes corporate and financial disclosures such as quarterly business updates, financial results, inducement grants under Nasdaq Listing Rule 5635(c)(4), amendments to equity plans, and senior leadership appointments. The company also announces participation in healthcare and investor conferences, where members of management discuss strategy and development programs.
By following ALGS news, readers can track clinical progress, preclinical findings, capital and governance actions, and organizational developments that shape Aligos Therapeutics’ efforts in liver and viral disease therapeutics.
Aligos Therapeutics (Nasdaq: ALGS), a clinical-stage biopharmaceutical company, announced that six of its abstracts have been accepted for presentation at the European Association for the Study of the Liver (EASL) Congress 2024, taking place from June 5-8 in Milan, Italy. The accepted abstracts include findings on their novel therapeutics for liver and viral diseases.
Highlighted abstracts involve the Capsid Assembly Modulator (CAM) ALG-000184, which has shown promising antiviral effects in chronic hepatitis B (CHB) patients. Notably, two abstracts have earned 'Top' recognition for their outstanding contribution: one on second-generation HBV siRNAs demonstrating improved profiles, and another on CAM-A molecules inducing rapid HBsAg reductions in animal models.
The presentations cover both preclinical and clinical research, reflecting Aligos' leadership in addressing unmet medical needs in liver diseases.
Aligos Therapeutics (Nasdaq: ALGS) has completed enrollment for its Phase 2a HERALD study of ALG-055009, targeting metabolic dysfunction-associated steatohepatitis (MASH). The study enrolled around 100 subjects with liver fibrosis. Topline safety and efficacy data are expected in early Q4 2024.
Dr. Rohit Loomba, a renowned expert in gastroenterology and hepatology, will serve as the Principal Investigator. The trial involves a double-blind, placebo-controlled design with subjects receiving one of four doses or placebo for 12 weeks. The primary endpoint is the relative change in liver fat content measured by MRI-PDFF.
The study aims to assess safety, pharmacokinetics, and other non-invasive biomarkers influenced by thyroid hormone receptor beta agonists. The completion of enrollment is a significant milestone for Aligos.
Aligos Therapeutics, a clinical stage biopharmaceutical company, reported recent business progress and financial results for the first quarter of 2024. They initiated the Phase 2a HERALD study of their drug candidate ALG-055009 and presented positive data on their other programs at scientific conferences. The company's cash balance remains strong to fund operations until the end of 2025.
Aligos Therapeutics, a clinical stage biopharmaceutical company, will announce its 1st Quarter 2024 financial results on May 7, 2024. The company focuses on developing therapeutics for liver and viral diseases.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.